Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited (ASX: BOT) is a Northbridge, Australia-based clinical stage medical dermatology company that develops safe and effective therapeutic treatment, for serious skin diseases, such as transdermal gels comprising BTX 1503 to treat serious acne in adults and teenagers; BTX 1308 for plaque psoriasis; BTX 1204 for atopic dermatitis; and BTX 1701 for mild acne.
The company has a market cap of AUD 87.1 million and ~ 757.42 million outstanding shares on the ASX. At the close of the market session on February 26th, the BOT stock traded at AUD 0.105, down 8.696%, indicating an intra-day fall of AUD 0.010. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Regardless, the stock performance has been performing reasonably decent over the past year with the return yields for the last three-month at 47.44% and for six-month at 16.16%. So far, BOT has generated a positive YTD return of 57.53%. For the previous quarter ended December 31st, 2018, the company had net cash and cash equivalents of AUD 13.53 million and reported strong progress across its product portfolio.
Monash IVF Group Limited
The Richmond, Australia-based Monash IVF Group Limited (ASX: MVF) provides human fertility services including assisted reproductive services (ARS), a significant component of fertility care; specialist women’s imaging; diagnostic ultrasound and other techniques to help patients. The company has a market cap of AUD 230.87 million. At the close of the trading session on February 26th, the MVF market price stood at AUD 0.985, up 0.51%, indicating an intra-day gain of AUD 0.005. Although the stock has generated a negative YTD return of 0.51%, the stock has been trending up since the last five days with an average yield of 4.26%.
For the six months ended December 31st, 2018, Monash IVF reported revenue of AUD 77.17 million with an EBITDA down by 9.8% to AUD 18.75 million. While the net profit from ordinary activities after tax attributable to members (NPAT) was down by 11.3% on the prior period to AUD 10.69 million, it exceeded the prescribed guidance provided at the AGM.
The Perth, Australia-based Nuheara Limited (ASX: NUH) is a global consumer wearables technology company which develops smart personal hearing devices based on proprietary and multi-functional intelligent hearing solutions. The company has a market cap of AUD 69.17 million on the ASX with ~ 960.66 million outstanding shares. With the close of the trading session on February 26th, the stock price of NUH last traded at AUD 0.071, down 1.389%, indicating an intra-day loss of AUD 0.001 and it has generated a positive YTD return of 1.41% so far.
Recently, Nuheara announced its results for the half-year ended December 2018 (H1 FY2019), highlighting an increase in the overall average sales price (ASP) per unit of all products from $ 181 in H1 FY2018 to $ 337 in H1 FY2019. The newly launched IQbuds BOOST™ represented 73% of all unit sales in the concerned period with an ASP above $ 400 per unit. The half-year revenue was posted at $ 1.42 million, and the company also made new sales appointments in Europe and North America.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.